GW-1100

CAS No. 306974-70-9

GW-1100( —— )

Catalog No. M33377 CAS No. 306974-70-9

GW-1100 is a selective GPR40 and FFAR1 antagonist for the study of diabetes and metabolic diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 44 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GW-1100
  • Note
    Research use only, not for human use.
  • Brief Description
    GW-1100 is a selective GPR40 and FFAR1 antagonist for the study of diabetes and metabolic diseases.
  • Description
    GW-1100 is a selective GPR40 antagonist with a pIC50 of 6.9.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    GPR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    306974-70-9
  • Formula Weight
    520.58
  • Molecular Formula
    C27H25FN4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (96.05 mM; Ultrasonic )
  • SMILES
    CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Stoddart LA, et al. Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5'-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol. 2007 Apr;71(?
molnova catalog
related products
  • APD 668

    APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.

  • GSK256073

    GSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist.

  • hGPR91 antagonist 3

    hGPR91 antagonist 3 is an orally active, potent, and selective hGPR91 antagonist. hGPR91 antagonist 3 is used to study hypertension, autoimmune diseases, and retinal angiogenesis.